Tirosina Quinase/Adaptador
Os inibidores de tirosina quinase e adaptadores são compostos que têm como alvo as tirosina quinases e suas proteínas adaptadoras associadas, que desempenham papéis fundamentais na sinalização celular, crescimento e diferenciação. Esses inibidores são ferramentas essenciais na pesquisa sobre o câncer, pois muitas tirosina quinases estão envolvidas nas vias de sinalização que impulsionam o crescimento e a metástase dos tumores. Ao inibir as tirosina quinases, esses compostos podem bloquear cascatas de sinalização críticas, oferecendo potenciais estratégias terapêuticas para vários tipos de câncer e outras doenças que envolvem sinalização celular anormal. Na CymitQuimica, oferecemos uma ampla gama de inibidores de tirosina quinase e adaptadores de alta qualidade para apoiar sua pesquisa em oncologia, biologia molecular e desenvolvimento de terapias direcionadas.
Subcategorias de "Tirosina Quinase/Adaptador"
- ALK(112 produtos)
- CSF-1R(42 produtos)
- EGFR(572 produtos)
- Receptor de Efrina(23 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- HER(5 produtos)
- Hck(3 produtos)
- IGF-1R(87 produtos)
- PDGFR(126 produtos)
- PYK2(7 produtos)
- Src(79 produtos)
- Receptor TAM(32 produtos)
- Tie-2(20 produtos)
- Receptor TrK(59 produtos)
- Tirosina Quinases(26 produtos)
- VEGFR(268 produtos)
- c-Fms(108 produtos)
- c-Kit(101 produtos)
- c-Met/HGFR(128 produtos)
- c-RET(51 produtos)
Exibir 13 mais subcategorias
Foram encontrados 1372 produtos de "Tirosina Quinase/Adaptador"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC EGFR degrader 10
CAS:<p>PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.</p>Fórmula:C49H65ClN10O7SCor e Forma:SolidPeso molecular:973.62EGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Fórmula:C38H47BrFN10O2PCor e Forma:SolidPeso molecular:805.72Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Pureza:95% - 95%Cor e Forma:LiquidH1-7 (histone H1 phosphorylation site), PKA Substrate
CAS:<p>H1-7 (histone H1 phosphorylation site), a synthetic polypeptide serving as a PKA substrate, demonstrates utility in PKA substrate applications [1] [2].</p>Fórmula:C31H58N14O9Cor e Forma:SolidPeso molecular:770.88Etevritamab
CAS:<p>Etevritamab is a monoclonal antibody that targets CD3E/EGFR.</p>Cor e Forma:LiquidCofetuzumab
CAS:<p>Cofetuzumab (PF-06523435) is a antibody targeting protein tyrosine kinase 7 (PTK7), which can be used to synthesize ADC compounds like cofetuzumab pelidotin.</p>Pureza:>95%Cor e Forma:Liquid[Pro3]-GIP (Mouse)
<p>GIP receptor blocker, 2.6μM IC50, hinders insulin release, regulates glucose in ob/ob mice, and enhances glucose tolerance.</p>Fórmula:C225H342N62O64SPureza:98%Cor e Forma:SolidPeso molecular:4971.62EGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Fórmula:C27H37FN8O2Cor e Forma:SolidPeso molecular:524.633PROTAC EGFR degrader 11
CAS:<p>PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.</p>Fórmula:C49H64ClFN10O7SCor e Forma:SolidPeso molecular:991.61cis-NVP-ADW742
CAS:<p>NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.</p>Fórmula:C28H31N5OCor e Forma:SolidPeso molecular:453.59PKI (5-24),amide
CAS:<p>PKI (5-24),amide is a 20-residue peptide, a potent PKA inhibitor with a Ki of 2.3 nM, derived from a cAMP inhibitor protein.</p>Fórmula:C94H149N33O30Cor e Forma:SolidPeso molecular:2221.4ErbB-2-binding peptide
CAS:<p>ErbB-2-binding peptide (HER2-binding peptide), a tumor-targeting peptide, holds potential for cancer research applications [1].</p>Fórmula:C43H60N8O11Cor e Forma:SolidPeso molecular:864.98pYEEI
<p>pYEEI, a tetrapeptide containing phosphotyrosine, binds to the SrcSH2 domain with a dissociation constant (Kd) of 100 nM and an inhibitory concentration (IC50) of 6.5 μM. This compound plays a crucial role in cancer research.</p>Fórmula:C25H36N3O14PCor e Forma:SolidPeso molecular:633.54SU 4981
CAS:<p>SU 4981 is an inhibitor of VEGFR and a modulator of tyrosine kinase activity.</p>Fórmula:C19H18N2O2Pureza:95.4%Cor e Forma:SoildPeso molecular:306.36MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Cor e Forma:SolidPeso molecular:993.47Herceptide
CAS:<p>Herceptide (HER2-targeting peptide), a peptide that targets HER2, can be conjugated with the near-infrared fluorescent dye indocyanine green (ICG), facilitating the development of theranostic agents.</p>Fórmula:C76H110N22O23Cor e Forma:SolidPeso molecular:1699.82DDR Inhibitor 2
<p>DDR Inhibitor 2 (compound 5a) is a potent inhibitor of the discoidin domain receptor (DDR) with an IC50 value of 0.125 μM, and it is applicable in fibrotic disease research.</p>Fórmula:C21H23N7OCor e Forma:SolidPeso molecular:389.19641EGFR T790M/L858R-IN-6
CAS:<p>EGFR T790M/L858R-IN-6 (compound 53), classified as a pyrimidine compound, serves as an effective inhibitor of EGFR T790M/L858R, demonstrating 90.88% inhibition of enzyme activity at a concentration of 0.05 μM [1].</p>Fórmula:C27H27N7O2Cor e Forma:SolidPeso molecular:481.55Fosgonimeton acetate
<p>Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).</p>Fórmula:C29H49N4O10PPureza:98.01%Cor e Forma:SolidPeso molecular:644.69cFMS Receptor Inhibitor IV
CAS:<p>cFMS Receptor Inhibitor IV is an inhibitor of c-Fms tyrosine kinase.</p>Fórmula:C22H26N4O2Pureza:99.70%Cor e Forma:SolidPeso molecular:378.47Simotinib hydrochloride
CAS:<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Fórmula:C25H27Cl2FN4O4Cor e Forma:SolidPeso molecular:537.41DP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Cor e Forma:LiquidPertuzumab
CAS:<p>Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2</p>Pureza:98.00%Cor e Forma:LiquidPeso molecular:148 kDaEGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Fórmula:C50H49N11O5SCor e Forma:SolidPeso molecular:916.06AZ14240475
<p>AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.</p>Fórmula:C23H15ClF2N6O2Cor e Forma:SolidPeso molecular:480.854Acrizanib
CAS:<p>Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2.</p>Fórmula:C20H18F3N7O2Pureza:98.71% - 99.64%Cor e Forma:SolidPeso molecular:445.4WAY-270360
CAS:<p>WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.</p>Fórmula:C22H19N3O3Pureza:98.05%Cor e Forma:SolidPeso molecular:373.4SJF 1528
CAS:<p>Potent EGFR & HER2 degrader; DC50 of 39.2 nM in OVCAR8, 736 nM in HeLa; has lapatinib, VHL ligand; inhibits HER2+ breast cancer (IC50=102 nM for SKBr3).</p>Fórmula:C55H57ClFN7O8SCor e Forma:SolidPeso molecular:1030.61Vasonatrin Peptide (VNP)
CAS:<p>Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity</p>Fórmula:C123H198N36O36S3Pureza:98%Cor e Forma:SolidPeso molecular:2865.37GW 583340
CAS:<p>GW 583340 is a potent and selective dual inhibitor of EGFR/ErbB2 tyrosine kinase with the advantage of oral dosability and antitumor effects.</p>Fórmula:C28H25ClFN5O3S2Pureza:98.68%Cor e Forma:SoildPeso molecular:598.11PF-04217903 phenolsulfonate
CAS:<p>PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Fórmula:C25H22N8O5SPureza:98%Cor e Forma:SolidPeso molecular:546.56Timigutuzumab
CAS:<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Cor e Forma:LiquidGefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Fórmula:C22H24ClFN4O41·5HClCor e Forma:SolidPeso molecular:517.59Zenocutuzumab
CAS:<p>Zenocutuzumab (MCLA-128) is a humanized antibody targeting HER2, used for research on tumors driven by NRG1 gene rearrangement.</p>Pureza:97%Cor e Forma:LiquidKemptide Phospho-Ser5
<p>Kemptide (Phospho-Ser5) is a phosphoreceptor peptide that is a specific substrate for camp-dependent protein kinase (PKA).</p>Fórmula:C32H62N13O12PPureza:98%Cor e Forma:SolidPeso molecular:851.89GIP, human
CAS:<p>Insulinotropic hormone from K-cells, binds GIP receptors, boosts insulin, affects lipids, and has antiapoptotic properties.</p>Fórmula:C226H338N60O66SPureza:98%Cor e Forma:SolidPeso molecular:4983.6PROTAC EGFR degrader 3
CAS:<p>Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.</p>Fórmula:C60H77N13O5SCor e Forma:SolidPeso molecular:1092.4Eflapegrastim
CAS:<p>Eflapegrastim: humanized IgG4 antibody and G-CSF that boosts neutrophils and shortens neutropenia.</p>Cor e Forma:LiquidEGFR-IN-42
<p>EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.</p>Fórmula:C49H53ClFN5O5Cor e Forma:SolidPeso molecular:846.43JBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Fórmula:C33H30F4N4O5SCor e Forma:SolidPeso molecular:670.67evobrutinib
CAS:<p>Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the</p>Fórmula:C25H27N5O2Pureza:98.03% - 99.58%Cor e Forma:SolidPeso molecular:429.51Anti-TrkB/NTRK2 Antibody
<p>Anti-TrkB/NTRK2 Antibody is a human-derived antibody produced in CHO cells, targeting TrkB. For the isotype control of Anti-TrkB/NTRK2 Antibody, refer to HumanIgG2kappa, Isotype Control.</p>Cor e Forma:Odour LiquidEGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Fórmula:C26H20ClFN4OSCor e Forma:SolidPeso molecular:490.98IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Cor e Forma:Odour LiquidInsulin efsitora alfa
CAS:<p>Insulin efsitora alfa(LY-3209590) is an IR agonist and a fusion protein that binds a novel single-chain insulin variant to the structural domain of human IgG Fc</p>Pureza:98.3% (SDS-PAGE); 98.1% (SEC-HPLC) - 98.3% (SDS-PAGE); 98.1% (SEC-HPLC)Cor e Forma:LiquidEGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Fórmula:C27H31N3O2Cor e Forma:SolidPeso molecular:429.24163MS9449
CAS:<p>MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.</p>Fórmula:C60H76ClFN10O8SPureza:98%Cor e Forma:SolidPeso molecular:1151.82MS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Fórmula:C50H59ClF4N8O14Cor e Forma:SolidPeso molecular:1107.5PKI(5-24)
CAS:<p>High affinity PKA inhibitor (Ki = 2.3 nM).</p>Fórmula:C76H129N31O28Pureza:98%Cor e Forma:SolidPeso molecular:1925.057YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Cor e Forma:Odour Liquid
